About Mallinckrodt (NYSE:MNK)
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio4.36757937183614
Forward P/E Ratio2.24
Sales & Book Value
Annual Sales$829.90 million
Price / Sales1.85
Cash Flow$0.26 per share
Price / Cash63.18
Book Value$47.57 per share
Price / Book0.34
Return on Equity14.79%
Return on Assets5.07%
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt's stock buyback program work?
Mallinckrodt announced that its board has authorized a stock repurchase plan on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 18.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.17. The company earned $793.90 million during the quarter, compared to analyst estimates of $808.93 million. Mallinckrodt had a return on equity of 14.79% and a net margin of 11.43%. The company's revenue was down 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.04 EPS. View Mallinckrodt's Earnings History.
When will Mallinckrodt make its next earnings announcement?
Where is Mallinckrodt's stock going? Where will Mallinckrodt's stock price be in 2018?
17 equities research analysts have issued 12-month target prices for Mallinckrodt's stock. Their forecasts range from $20.00 to $98.00. On average, they expect Mallinckrodt's stock price to reach $43.74 in the next year. View Analyst Ratings for Mallinckrodt.
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)
- 2. Cantor Fitzgerald analysts commented, "Mallinckrodt announced today that it is selling certain hemostasis products to Baxter (BAX, Not Covered), including Recothrom and PreveLeak, for ~ $185MM, with $153MM upfront and the rest in potential milestones. The company will also discontinue marketing of Raplixa and evaluate strategic options for the product." (1/8/2018)
- 3. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Indivior (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen (RGEN), TherapeuticsMD (TXMD), Assembly Biosciences (ASMB), Eagle Pharmaceuticals (EGRX), Rockwell Medical (RMTI), Novan (NOVN), Macrocure (MCUR), CorMedix (CRMD), DARA Biosciences (DARA), Check Cap (CHEK) and Omthera Pharmaceuticals (OMTH).
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Melvin D. Booth Ph.D. CPA, Independent Chairman of the Board (Age 71)
- Mark C. Trudeau, President, Chief Executive Officer, Director (Age 55)
- Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President (Age 46)
- Ian J. Watkins, Chief Human Resource Officer (Age 54)
- Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies (Age 56)
- Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer (Age 51)
- Steven Romano, Executive Vice President and Chief Scientific Officer (Age 57)
- Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics (Age 47)
- Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases (Age 53)
- Raymond J. Furey, Chief Compliance Officer (Age 48)
Who owns Mallinckrodt stock?
Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.99%), Alliancebernstein L.P. (2.77%), LSV Asset Management (2.76%), Two Sigma Investments LP (1.44%), Arrowstreet Capital Limited Partnership (1.43%) and Brandywine Global Investment Management LLC (1.25%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Who sold Mallinckrodt stock? Who is selling Mallinckrodt stock?
Mallinckrodt's stock was sold by a variety of institutional investors in the last quarter, including HealthCor Management L.P., BlackRock Inc., UBS Asset Management Americas Inc., Deutsche Bank AG, Alliancebernstein L.P., Teacher Retirement System of Texas, American Financial Group Inc. and Swiss National Bank. View Insider Buying and Selling for Mallinckrodt.
Who bought Mallinckrodt stock? Who is buying Mallinckrodt stock?
Mallinckrodt's stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Two Sigma Advisers LP, LSV Asset Management, Spark Investment Management LLC, Renaissance Technologies LLC and Royce & Associates LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy Mallinckrodt stock?
Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of Mallinckrodt stock can currently be purchased for approximately $16.16.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $1.51 billion and generates $829.90 million in revenue each year. The company earns $-153,200,000.00 in net income (profit) each year or $3.70 on an earnings per share basis. Mallinckrodt employs 4,500 workers across the globe.
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (MNK)MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mallinckrodt (NYSE:MNK) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Buy|
|Consensus Rating Score: ||2.35||2.39||2.44||2.93|
|Ratings Breakdown: ||1 Sell Rating(s)|
9 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$43.74||$45.81||$49.31||$70.54|
|Price Target Upside: ||140.97% upside||104.58% upside||136.14% upside||84.41% upside|
Mallinckrodt (NYSE:MNK) Consensus Price Target History
Mallinckrodt (NYSE:MNK) Analyst Ratings History
(Data available from 2/24/2016 forward)
Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart
Mallinckrodt (NYSE MNK) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||$1.80||$1.97||$808.93 million||$793.90 million||View||N/A|
|8/8/2017||Q2 2017||$1.73||$1.85||$829.56 million||$824.50 million||View||Listen|
|5/8/2017||Q1 2017||$1.63||$1.68||$781.23 million||$810.90 million||View||Listen|
|2/7/2017||Q117||$1.82||$1.91||$827.12 million||$829.90 million||View||Listen|
|11/29/2016||Q416||$1.98||$2.04||$880.10 million||$887.20 million||View||Listen|
|8/2/2016||Q316||$2.01||$2.20||$920.35 million||$970.60 million||View||Listen|
|5/3/2016||Q216||$1.72||$2.01||$878.70 million||$918.00 million||View||Listen|
|2/2/2016||Q116||$1.78||$2.09||$888.33 million||$915.00 million||View||Listen|
|11/23/2015||Q415||$1.77||$1.84||$869.41 million||$882.40 million||View||Listen|
|8/4/2015||Q315||$1.82||$2.05||$983.81 million||$965.10 million||View||Listen|
|5/5/2015||Q215||$1.48||$1.72||$860.89 million||$909.90 million||View||Listen|
|2/3/2015||Q115||$1.57||$1.84||$880.12 million||$866.00 million||View||Listen|
|11/19/2014||Q414||$1.41||$1.68||$759.04 million||$789.00 million||View||Listen|
|8/7/2014||Q314||$0.86||$1.20||$278.80 million||$653.10 million||View||Listen|
|5/8/2014||Q214||$0.79||$0.95||$566.50 million||$557.80 million||View||Listen|
|2/6/2014||Q1||$0.66||$0.88||$539.24 million||$540.20 million||View||Listen|
|11/7/2013||$0.85||$1.02||$572.57 million||$552.20 million||View||Listen|
|8/9/2013||Q3 2013||$0.78||$0.49||$557.22 million||$570.00 million||View||Listen|
Mallinckrodt (NYSE:MNK) Earnings Estimates
2018 EPS Consensus Estimate: $6.89
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Mallinckrodt (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com
Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 97.38%
Mallinckrodt (NYSE MNK) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/28/2017||Dr Kneeland Youngblood||Director||Buy||4,560||$21.94||$100,046.40||19,789|| |
|11/13/2017||Joann A Reed||Director||Buy||1,000||$21.50||$21,500.00||15,554|| |
|11/13/2017||Steven J. Romano||VP||Buy||2,000||$21.96||$43,920.00|| |
|11/10/2017||Mark Trudeau||CEO||Buy||5,000||$22.28||$111,400.00|| |
|11/9/2017||David R Carlucci||Director||Buy||10,000||$21.83||$218,300.00||26,020|| |
|11/9/2017||Michael-Bryant Hicks||General Counsel||Buy||7,900||$20.80||$164,320.00|| |
|8/30/2017||Meredith B. Fischer||Insider||Buy||1,280||$39.63||$50,726.40|| |
|6/9/2017||Steven J. Romano||VP||Buy||1,000||$39.88||$39,880.00|| |
|6/8/2017||Hugh M. O'neill||VP||Buy||1,000||$40.24||$40,240.00|| |
|6/5/2017||Coleman N Lannum III||VP||Buy||500||$39.33||$19,665.00||31,455|| |
|6/2/2017||Coleman N Lannum III||VP||Buy||1,350||$42.89||$57,901.50||30,955|| |
|5/12/2017||Coleman N. Lannum III||VP||Buy||1,968||$46.20||$90,921.60|| |
|3/10/2017||Matthew K. Harbaugh||CFO||Buy||600||$49.19||$29,514.00|| |
|3/7/2017||Michael-Bryant Hicks||General Counsel||Buy||290||$50.35||$14,601.50|| |
|2/23/2017||Meredith B. Fischer||Insider||Buy||2,000||$54.34||$108,680.00|| |
|2/14/2017||Mark Trudeau||Insider||Buy||1,000||$50.47||$50,470.00|| |
|2/10/2017||Steven J. Romano||VP||Buy||1,000||$49.68||$49,680.00|| |
|5/10/2016||Hugh M O'neill||VP||Buy||1,653||$60.99||$100,816.47||15,623|| |
|5/10/2016||Matthew K Harbaugh||CFO||Buy||500||$59.37||$29,685.00||56,036|| |
|5/6/2016||Mark Trudeau||CEO||Buy||1,000||$56.02||$56,020.00||192,546|| |
|5/6/2016||Steven J Romano||VP||Buy||900||$56.00||$50,400.00||9,291|| |
|3/4/2016||Coleman N Lannum III||VP||Buy||2,600||$62.63||$162,838.00||20,556|| |
|2/26/2016||Meredith B Fischer||VP||Buy||1,400||$69.80||$97,720.00||17,643|| |
|2/12/2016||Coleman N Lannum III||VP||Buy||600||$59.66||$35,796.00||17,940|| |
|2/10/2016||Coleman N Lannum III||VP||Buy||1,300||$62.58||$81,354.00||17,340|| |
|2/9/2016||Matthew K. Harbaugh||CFO||Buy||1,300||$63.00||$81,900.00|| |
|2/8/2016||Coleman N. Lannum III||VP||Buy||800||$66.37||$53,096.00|| |
|12/22/2015||Coleman N Lannum III||SVP||Buy||500||$72.50||$36,250.00||11,266|| |
|12/11/2015||Terrance L Carlson||General Counsel||Buy||1,000||$69.10||$69,100.00||2,549|| |
|12/2/2015||Gary M. Phillips||VP||Buy||1,000||$72.17||$72,170.00||7,728|| |
|11/30/2015||Mark Trudeau||CEO||Buy||1,350||$65.89||$88,951.50||167,526|| |
|11/27/2015||Coleman N Lannum III||SVP||Buy||1,200||$66.86||$80,232.00||9,986|| |
|11/27/2015||Meredith B Fischer||VP||Buy||2,200||$66.93||$147,246.00||14,280|| |
|11/27/2015||Terrance L Carlson||General Counsel||Buy||1,000||$66.54||$66,540.00||1,453|| |
|8/25/2015||Hugh M O'neill||SVP||Buy||1,197||$83.52||$99,973.44||9,015|| |
|8/25/2015||Mark Trudeau||CEO||Buy||1,000||$83.08||$83,080.00||166,176|| |
|8/21/2015||Coleman N Lannum III||SVP||Buy||2,375||$88.52||$210,235.00||7,361|| |
|8/21/2015||Mark Trudeau||CEO||Buy||2,000||$88.45||$176,900.00||165,176|| |
|6/4/2015||Coleman N Lannum III||VP||Buy||1,300||$126.41||$164,333.00|| |
|6/2/2015||Matthew K Harbaugh||CFO||Sell||22,106||$128.64||$2,843,715.84|| |
|5/18/2015||Mario D Saltarelli||VP||Sell||4,580||$127.44||$583,675.20|| |
|5/13/2015||Don M Bailey||Director||Sell||51,417||$122.45||$6,296,011.65|| |
|5/11/2015||Sandra L Hatten||VP||Sell||2,024||$122.29||$247,514.96|| |
|4/13/2015||Don M Bailey||Director||Sell||40,000||$127.61||$5,104,400.00|| |
|3/13/2015||Don M Bailey||Director||Sell||40,000||$123.40||$4,936,000.00|| |
|2/13/2015||Don M Bailey||Director||Sell||33,891||$114.63||$3,884,925.33|| |
|2/2/2015||Mark Trudeau||CEO||Sell||11,925||$105.94||$1,263,334.50|| |
|1/9/2015||Mark Trudeau||CEO||Sell||15,720||$102.00||$1,603,440.00|| |
|12/22/2014||Peter G Edwards||VP||Sell||1,265||$99.69||$126,107.85|| |
|12/18/2014||Mark Trudeau||CEO||Sell||13,831||$93.59||$1,294,443.29|| |
|9/10/2014||Raymond J Furey||VP||Sell||5,441||$85.90||$467,381.90|| |
|9/8/2014||Don M Bailey||Director||Sell||221,177||$85.23||$18,850,915.71|| |
|9/5/2014||Raymond J Furey||VP||Sell||15,000||$85.47||$1,282,050.00|| |
|9/5/2014||Virgil D Thompson||Director||Sell||25,000||$83.76||$2,094,000.00|| |
|9/2/2014||Raymond J Furey||VP||Sell||10,303||$81.61||$840,827.83|| |
|8/29/2014||Raymond J Furey||VP||Sell||4,840||$80.90||$391,556.00|| |
|8/19/2014||Joseph A Zaccagnino||Director||Buy||3,000||$71.06||$213,180.00|| |
|8/13/2014||Paulson & Co Inc||Major Shareholder||Buy||132,100||$69.80||$9,220,580.00|| |
|8/12/2014||J Martin Carroll||Director||Buy||2,000||$69.24||$138,480.00|| |
|8/12/2014||Paulson & Co Inc||Major Shareholder||Buy||467,900||$68.78||$32,182,162.00|| |
|8/11/2014||Paulson & Co Inc||Major Shareholder||Buy||207,900||$69.70||$14,490,630.00|| |
|8/7/2014||Paulson & Co Inc||Major Shareholder||Buy||700,200||$70.15||$49,119,030.00|| |
|8/1/2014||Paulson & Co Inc||Major Shareholder||Buy||275,000||$69.60||$19,140,000.00|| |
|6/11/2014||Melvin D Booth||Director||Buy||4,000||$76.05||$304,200.00|| |
|5/9/2014||Paulson & Co Inc||major shareholder||Buy||786,207||$73.63||$57,888,421.41|| |
|2/3/2014||Mark Trudeau||CEO||Sell||14,890||$56.12||$835,626.80|| |
Mallinckrodt (NYSE MNK) News Headlines
Mallinckrodt (NYSE:MNK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement
Mallinckrodt (NYSE MNK) Stock Chart for Saturday, February, 24, 2018